News | May 30, 2014

Recall Issued for Alere INRatio2 PT/INR Professional Test Strips

Results disagree with confirmed PT/INR reference test results performed by central laboratory

May 30, 2014 — Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor. This recall is expected to cause a shortage of test strips for the Alere INRatio2 professional PT/INR testing. Alere will transition customers from the current Alere INRatio2 PT/INR professional test strip to the Alere INRatio PT/INR test strip, which is not affected by the recall and is used by patient self-testers for home INR monitoring but has also been validated for professional use.

The affected test strips were manufactured from Aug. 22, 2013, through April 2, 2014, and distributed from Aug. 26, 2013, through April 2, 2014.

The Alere lNRatio2 PT/INR monitoring system (professional use) is used for quantitative determination of international normalized ratio (INR) in fresh, capillary whole blood to monitor the effect of warfarin on clotting time (prothrombin time). The system is intended for use outside of the body (in vitro diagnostic use) and not intended to be used for screening purposes. It is also not intended for use in patients who are transitioning from heparin treatment to warfarin therapy.

Initiated in April, the recall is due to complaints of patients who had a therapeutic or near-therapeutic INR result with the Alere INRatio2 PT/INR professional test strip but a significantly higher INR result (outside of therapeutic range) when retesting was performed by a central laboratory because of deterioration in the patient’s clinical condition. Use of this affected product may cause serious adverse health consequences, including death. At the time of writing Alere San Diego received nine reports of malfunctions; six injuries and three deaths caused by bleeding.

On April 17, 2014, Alere sent an Urgent Medical Device Recall letter to all affected customers by fax, email or direct mail. The letter identified the product, problem and the actions to be taken. Customers were requested to complete and sign a Reply Form that was included with the letter. Alere requested the completed form be sent by fax or by email.

For more information: www.inr-care.com

Related Content

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Overlay Init